Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
Phase 3 N=780 Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…
Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer
Phase 3 N=300 Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes for Subjects Receiving Synflorix Vaccine Co-administered With Tritanrix-HepB/Hib and Polio Sabin…
Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…
Phase 3 N=2,068 Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Phase 3 N=1,255 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants
Phase 4 N=162 The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
Phase 2 N=884 A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Pneumococcal Infection
Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events — 148; 153; 187; 213 participants
Phase 2 N=460 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
Phase 2 N=444 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 — 7.3; 3.6; 3.6; 3.2 percentage of participants
Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants
Phase 3 N=1,988 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 25.5; 24.6; 21.5; 22.3 Percentage of participants
Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
Pneumococcal Infections
Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer
Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Pneumococcal Infections
Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0) — 81; 55; 55; 49 geometric mean titer
Phase 3 N=331 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
HIV Infections · Pneumococcal Infections
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC…
Phase 1 N=86 Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
Pneumococcal Infections
Primary: Immune Responses — 1.95; 1.69; 1.22; 0.78 ug/mL
Phase 3 N=206 A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
Pneumococcal Infections
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years — 21.3; 10.6; 10.6; 0.0…
Phase 2 N=750 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Pneumococcal Immunization
Primary: Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA — 128; 127; 158; 254 Titer
Phase 3 N=286 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae…
Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
Vaccines, Pneumococcal
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 32.1; 30.0; 30.4; 36.7 Percentage of Participants
Phase 2 N=951 Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes During the Primary Phase of the Study — 1.54; 1.59; 1.37; 2.18 µg/mL
N/A N=2,509 Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting
Community Acquired Pneumonia
Primary: Improving Pneumococcal Vaccination Rates Following Focused Health Education of Staff and Patients — 1096 participants — p=<.0001
Phase 3 N=3,902 Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts — 7.3; 6.2; 8.2; 5.4 percentage of participants
Phase 3 N=600 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations >= 0.20 Microgram Per Milliliter (µg/mL)…
Phase 1 N=394 Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention — 0.0; 0.0; 0.0; 2.3 Percentage of participants